Company
Every investor coverage indicates participated in a round Brandon Capital Partners raised.
Companies Brandon Capital Partners acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Brandon Capital Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
America's medicines regulator has approved Currus Biologics to begin human trials of CUR-001, its solid-tumour CAR T-cell therapy combination, with dosing expected from early 2027.
Australian biotech Currus Biologics has won US regulator clearance to begin human testing of its lead cancer therapy, CUR-001; the company's backers include Brandon Capital, Main Sequence and Uniseed.
Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.
ENA Respiratory receives a USD 4.38 million U.S. Department of Defense agreement to develop an intranasal dry powder antiviral; its past Series A backers are also recalled.
Antiviral nasal spray developer ENA Respiratory has joined the Blue Knight program run by JLABS and BARDA, the first Australian company selected; background notes recall its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.
Brandon Capital reports that ENA Respiratory has become the first Australian company chosen for BLUE KNIGHT, a JLABS-BARDA initiative supporting its intranasal broad-spectrum antiviral spray INNA-051.
Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.
New Zealand cancer biotech Amaroq Therapeutics had its lncRNA drug targets independently validated by CSIRO, according to this profile, which also recalls its $14 million seed round and support from Callaghan Innovation.
ENA Respiratory has begun a Phase 2a influenza-challenge trial in the UK of its INNA-051 antiviral nasal spray; the article also recalls its Series A backing by Brandon Capital, Minderoo Foundation and Uniseed.
ENA Respiratory has begun dosing healthy adults in a UK influenza challenge trial of its INNA-051 antiviral nasal spray, with a COVID-19 study to follow; the release also notes the company's earlier Series A backing.
Horizon 3 Biotech, an Australian life sciences venture fund, announces Dr Tam Nguyen joining its investment committee, citing his board, research commercialisation and healthcare experience and past Brandon Capital secondment.